Hyperfine, Inc. (HYPR) Q3 2026 Earnings Call Transcript
Hyperfine faces a challenging path to profitability as it struggles to scale its proprietary low-field MRI technology amidst volatile revenue growth and significant operational overhead.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 9, 2026 | -$0.07+15.2% vs -$0.08 | $6M+2.1% vs $6M |
Q3 2026 Aug 6, 2026 | -$0.09+0.0% vs -$0.09 | $4M-5.6% vs $4M |
Q2 2026 May 12, 2026 | -$0.09+0.0% vs -$0.09 | $4M+10.3% vs $4M |
Q2 2026 Mar 18, 2026 | -$0.08+0.0% vs -$0.08 | $5M+2.7% vs $5M |
Hyperfine, Inc. (HYPR) Q3 2026 Earnings Call Transcript
Hyperfine NASDAQ: HYPR reported record third-quarter revenue and gross margin, while narrowing its operating loss and reducing cash burn as sales of its portable brain MRI system increased across its U.S. and international markets.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced third quarter 2026 financial results and provided a business update. “Q3 2026 marked the beginning of a new trajectory for Hyperfine. We delivered record revenue, gross profit, and gross margin, and for the first time quarterly revenue exceeded net.

Hyperfine (NASDAQ: HYPR - Get Free Report) and Sysmex (OTCMKTS:SSMXY - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends. Profitability This table compares Hyperfine and Sysmex's net margins, return
Benchmark HYPR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Hyperfine, Inc. (HYPR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.56 | $47.3M | -2.00 | 5.22% | -156.42% | -82.89% | — | |
| $23.78 | $1.35B | -11.87 | 37.22% | -32.6% | -33.23% | — | |
| $11.14 | $1.29B | -10.69 | 8.28% | -16.78% | -35.81% | — | |
| $18.30 | $1.35B | 6.82 | 18.52% | 43.79% | 15.84% | — | |
| $11.06 | $138.18M | -47.18 | 14.52% | -7.12% | -74.71% | — | |
| $81.84 | $36.97B | 21.06 | 4.84% | 8.54% | 15.87% | 0.17% |
Hyperfine, Inc. (HYPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Hyperfine, Inc. (HYPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 9, 2026·SEC
Aug 6, 2026·SEC
May 21, 2026·SEC
Get notified when HYPR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Hyperfine, Inc. (HYPR) stock FAQ — growth, dividends, profitability & financials explained
Hyperfine, Inc. (HYPR) reported $19.1M in revenue over the trailing twelve months. Revenue was $13.6M in fiscal year 2025.
Hyperfine, Inc. (HYPR) grew revenue by 80.0% over the trailing twelve months, compared with the twelve months before.
No. Hyperfine, Inc. (HYPR) reported a net loss of $29.8M over the trailing twelve months.
Hyperfine, Inc. (HYPR) had a return on equity (ROE) of -82.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Hyperfine, Inc. (HYPR) had negative free cash flow of $27.9M over the trailing twelve months.